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Abstract 
Aim: To analyse the timing of cardiac troponin (cTn) measurements in high‑risk and cTn‑positive acute coronary 
syndromes without persistent ST‑segment elevation (NSTE‑ACS) in two structurally different German chest pain units 
(CPUs), contrasting an urban university maximum care and a rural regional primary care facility.
Methods: All patients encoded as NSTEMI during the year 2013 were retrospectively enrolled in two centres: site 
(I)—centre of maximum care in an urban university setting and site (II)—centre of primary care in a rural regional care 
setting. Data acquisition included time intervals from admission to baseline cTn and first and second cTn control as 
well as type and timing of invasive management.
Results: The median times (site I vs. site II) from admission to cTn result announcement were 26.5 vs. 33.0 min 
(p = 0.02) for baseline, 4 vs. 4 h (p = 0.43) for the first and 11.0 vs. 16.5 h (p = 0.03) for the second control. Timely 
announcement, as recommended by guidelines, was available in 86.9 % at baseline, 59.4 % for the first or 41.1 % for 
the second cTn control. Rates and timing of invasive management were independent from the time point of positive 
cTn announcement (p = 0.51 and p = 0.68, respectively).
Conclusions: German CPUs provide timely identification of cTn‑positive patients in a narrow and guideline‑adherent 
time frame using a rapid rule‑out protocol. Especially, baseline and early cTn timing was comparable between the 
urban university maximum care and the rural regional primary care facility without relevant impact on guideline‑con‑
forming invasive management, underlining the high standard of care in those highly professional institutions.
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Background
Elevation of cardiac troponin (cTn) directly affects ade-
quate timing of invasive management in patients with 
acute coronary syndromes without persistent ST-seg-
ment elevation (NSTE-ACS), distinguishing between 
myocardial infarction (MI) without persistent ST-seg-
ment elevation (NSTEMI) and unstable angina pecto-
ris (UAP) [1]. Early identification of NSTEMI patients 
ensures rapid decision-making and initiation of coronary 
angiography (CA) and has been shown to improve clini-
cal outcome [2–4]. The diagnostic cut-off is defined as 
a cTn measurement exceeding the 99th percentile of a 
normal reference population using an assay with a coef-
ficient of variation of ≤10 % at the upper reference limit 
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cTn-negative or cTn-positive patients, the use of sensi-
tive contemporary or highly sensitive cTn requires fur-
ther detection and interpretation of a rise or fall in the 
cTn levels over time [8]. Different protocols indicating 
correct timing of cTn measurement have been evalu-
ated. As far as the timing is concerned, as to the current 
guidelines, the high sensitivity of modern tests allows for 
a rapid rule-out protocol including cTn measurements at 
baseline and 3 h after admission [3, 9, 10]. Besides a rapid 
rule-out regimen, for the time of patient inclusion (2013) 
the German Cardiac Society (GCS) also proposed labora-
tory measurement after 6–12  h [11]. As far as dynamic 
changes of cTn levels are concerned, for both, sensitive 
contemporary and highly sensitive cTn, differences of the 
relative delta values identifying NSTEMI patients have 
been implemented.
Following a broad offensive of the GCS, specialized 
chest pain units (CPUs) have been developed and, now, 
are thought to ensure quality-of-care in patients with 
acute coronary syndrome (ACS), providing dedicated 
standard operating procedures (SOPs) for prompt iden-
tification and treatment of patients with an ischaemic 
aetiology of chest pain, especially for those with acute 
MI [12]. Individual SOPs are obliged to fulfil current 
guidelines including timing and interpretation of cTn 
measurements [9, 11]. However, as to recent registry 
data, guideline-conforming management still needs to be 
strengthened even in these highly professional units [13, 
14].
The current study aimed to determine the implementa-
tion of standardized cTn measurement protocols in two 
exemplary German CPUs, thereby focusing on real-life 
timing of cTn sample collection. Moreover, the study 
aimed to disclose possible differences in a board-certified 
urban university maximum care versus non-certified 
rural regional primary care setting.
Methods
Study design
Consecutive all-comers with the final diagnosis 
“NSTEMI” (I21.4) according to the ICD-10-codes admit-
ted during the year 2013 were retrospectively enrolled. 
After standardized evaluation of the documentation for 
consistency and completeness by two observers (F.R., 
F.B.), only patients with clinical signs suggestive of ACS 
according to the European Society of Cardiology (ESC) 
guidelines with or without electrocardiographic changes 
indicative of ischaemia, but without ST-segment eleva-
tion, were finally included [1]. Patients with originally 
unstable angina pectoris reflected by initial cTn above the 
lower limit without rise or fall of ≤20 % within the con-
trols or by initial cTn below the lower limit control with-
out rise of ≤20 % were excluded.
In general, enrolment was performed in two differ-
ent sites: site (I)—a centre of maximum care in an urban 
university setting (University Hospital Münster) and site 
(II)—a centre of primary care in a rural regional care set-
ting (Arnsberg Medical Centre). In 2013, the department 
of cardiology of centre I took care of more than 6000 
patients in an in-patient and more than 10,000 patients in 
an out-patient setting, whereas the corresponding depart-
ment of centre II provided in-patient medical care in over 
5000 patients and out-patient care in over 4000 patients. 
Both sites provide dedicated CPU pathways ensuring rapid 
and focused assessment of patients with acute thoracic 
pain based on the local recommendations of the GCS. 
Only centre I has been board-certified by the GCS [11].
Troponin measurement and resulting subgroups
Patients were subclassified according to different dynamics 
of cTn levels over time and due to different tests used at the 
two sites
Site I used a sensitive contemporary assay (ADVIA Cen-
taur TnI-Ultra, Siemens Healthcare) [15, 16]. The val-
ues of ≤0.04  ng/ml were judged as negative and values 
≥0.05  ng/ml were judged as positive. For this centre, 
entities were defined as follows: (1) NSTEMI—initial cTn 
above 0.04 ng/ml, control with a rise or fall of >20 %, (2) 
NSTEMI—initial cTn below 0.04  ng/ml, control with a 
rise of >20 %, (3) high-risk (hr)-NSTE-ACS—initial cTn 
below 0.04  ng/ml, no further control because of prior 
invasive regimen and (4) hr-NSTE-ACS—initial cTn 
above 0.04  ng/ml, no further control because of prior 
invasive management.
Site II used a high-sensitivity assay (Troponin T hs, 
Roche Diagnostics) [17, 18]. For this assay, the values of 
<0.014  ng/ml were judged as negative, values between 
0.014 ng/ml and 0.05 ng/ml were judged as an observa-
tion zone and values >0.05 ng/ml were judged as positive. 
Except for the additional group (b) [NSTEMI—initial cTn 
within the observation zone, control with a rise or fall of 
>50 %], entities were defined analogue to centre I).
Timing of troponin measurement and coronary 
angiography
For cTn measurements, times were assessed from admis-
sion until the announcement of results according to the 
electronic documentation, accordingly including labora-
tory turn-around times. Guideline adherence was defined 
as follows: admission till announcement of baseline 
results: <1  h (45–60  min laboratory turn-around time); 
admission till announcement of the results of the first 
control: <4 h (control after 3 h plus 1 h laboratory turn-
around time) and admission till announcement of the 
results of the second control <13 h (control after 6–12 h 
plus 1 h laboratory turn-around time).
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Timing of CA was assessed for the time interval from 
admission to the beginning of CA (puncture times). 
Guideline-adherent timing of CA was defined as punc-
ture within the first 24 h after admission [1].
Statistics
Descriptive statistics are based on the available cases. 
The median with lower and upper quartiles was used for 
continuous variables without standard deviation. Cat-
egorical variables were described by absolute frequen-
cies and percentages. For two independent variables, the 
Mann–Whitney U test was used. Categorical variables 
were tested using the Fisher exact test. p values ≤0.05 
were considered significant without adjustment for mul-
tiple testing. Statistical computations were performed 
using SPSS for Windows (version 22.0).
Ethical considerations
The aforementioned protocol was reviewed by the local 
Ethics Committee (i.e. Ärztekammer Westfalen-Lippe 
and University of Münster, Germany). Given that we 
only used anonymized clinical routine data from the 
patients’ hospital records without additional examina-
tions, informed consent by the patients is not required 
according to § 6 (2) “Gesundheitsdatenschutzgesetz” 
(health data protection act) North Rhine-Westphalia, 
Germany. Therefore, the Ethics Committee considers 
the application and issue of an ethical approval as not 
necessary.
Results
A total of 88 patients in site I and 76 patients in site II 
fulfilled the inclusion criteria. Absolute numbers per 
group were as follows (site I vs. site II): groups a–c 
(NSTEMI)—42 vs. 54 patients and groups d–e (hr-
NSTE-ACS)—42 vs. 22 patients.
Valid cTn measurements were available in all patients 
at baseline and at the time of first control unless hr-
NSTE-ACS with prior CA. Results of a second con-
trol were available in 35  %, adjusted for hr-NSTE-ACS 
patients with CA prior to second control and consistent 
diagnosis of NSTEMI after the first control in 92 %.
Results from baseline cTn were available after a median 
time of 29 min (17–43 min) with significantly lower time 
intervals (site I, 26.5 min (17–37 min) vs. site II, 33 min 
(19–52 min); p = 0.02; Fig. 1a) associated with a signifi-
cantly higher percentage of cTn result announcements in 
time in centre I. The median time intervals from admis-
sion to result of the first and second control were 4  h 
(4–6 h) and 14 h (10–21 h), respectively. Whereas there 
was no significant difference concerning the first con-
trol (site I, 4 h (3–5 h) vs. site II, 4 h (3.5–6 h); p = 0.43; 
Fig.  1b), time intervals of the second control again 
differed significantly between both centres (site I, 11  h 
(8–14 h) vs. site II, 16.5 h (10–22 h); p =  0.03; Fig. 1c). 
When analysing percentages of guideline-adherent tim-
ing of cTn measurements, there was no significant differ-
ence at the time of first and second control. A detailed 
subgroup analysis of time intervals and guideline adher-
ence in timing is shown in Tables 1, 2.
Analysis of CA timing within the NSTEMI subset 
disclosed neither any significant difference between 
the two sites (p =  0.55) nor between diagnoses after 
the first or second cTn control (p =  0.68; Table  3). 
Fig. 1 Boxplot diagrams visualizing differences of time intervals 
from admission to results at baseline a, first b and second c cTn 
control. site I—centre of maximum care in an urban university setting 
(University Hospital Münster); site II—centre of primary care in a rural 
regional setting (Arnsberg Medical Center), asterisk indicates statisti‑
cally significance. cTn cardiac troponin
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Guideline-adherent timing of CA could be achieved in 
59.1 % (site I, 52.5 % vs. site II, 64.6 %; p = 0.76; Table 4) 
in those NSTEMI patients with final diagnosis after the 
first control. Later diagnosis of NSTEMI due to relevant 
cTn dynamics not until the second control did not lead 
to lower rates of adequate CA timing (59.1 % vs. 62.5 %; 
p = 0.71; Table 4).
Including both NSTEMI and hr-NSTE-ACS patients, 
an invasive strategy was chosen in 98.8  % of patients 
(site I, 98.8 % vs. site II, 98.7 %, p = 0.65). Rates of per-
cutaneous coronary intervention (PCI) were 64.3  % 
(site I) and 61.8 % (site II, p = 0.90), respectively. Cor-
onary artery bypass graft (CABG) placement was sig-
nificantly more often performed in site II (site I, 3.6 % 
vs. site II, 16.7  %, p  =  0.02). For NSTEMI only, rates 
of intervention were nearly similar in cTn-positive 
patients ensured by the first or second control (71.6 vs. 
87.5 %; p = 0.51) and between both sites (site I, 70.0 % 
vs. site II, 72.9 %; p = 0.82, Table 5). CABG procedures 
were more often performed in site II (site I, 2.5  % vs. 
site II, 16.7  % for NSTEMI ensured by first control, 
p < 0.01; site I, 0 vs. 16.7 % for NSTEMI ensured by the 
second control).
Discussion
The implementation of specialized CPUs has been shown 
to improve the prognosis of patients with ACS [19, 20]. 
These units allow a prompt identification and treatment 
of patients with suspected ACS by use of standardized 
diagnostic and therapeutic protocols [21]. Contempo-
rary, more sensitive cTn assays allow a more rapid and 
more precise diagnosis of NSTE-ACS patients [22, 23]. 
The current guidelines recommend a rapid rule-out pro-
tocol within three hours after presentation using high-
sensitive cTn assays [1]. Our study analysed the “real-life” 
situation for the timing of the diagnosis and invasive 
approach for NSTEMI patients in two German centres, 
a centre of maximum care in an urban university setting 
and a centre of primary care in a rural regional care set-
ting. Our study carries the following key messages: (1) 
in about 90 % of patients the announcement of baseline 
cTn results was possible within one hour as requested 
by guidelines; (2) the results of the first cTn control were 
available in a guideline-adherent median time frame of 
about four hours; however, result announcement was still 
considered as too late in about 40  % of the cases; (3) a 
second cTn control was necessary in roughly one-third of 
the patients only; nonetheless, result announcement was 
too late in nearly half of the patients included; (4) there 
was a significant difference between the two contrast-
ing exemplary sites at baseline and the second control 
in favour of faster announcement of cTn results within 
the university setting; and (5) most remarkably, the dif-
ferent timelines for the announcement of troponin levels 
between both sites, however, had no impact on the guide-
line-conforming timing of an invasive approach.
Table 1 Turn-around times  of cTn samples at  baseline 
and  after the first and  second control in  favour of  faster 
results in centre I
site I: centre of maximum care in an urban university setting (University Hospital 
Münster); site II: centre of primary care in a rural regional setting (Arnsberg 
Medical Center)
subgroups: a–c myocardial infarction without persistent ST-segment elevation 
(NSTEMI), d–e acute coronary syndromes without persistent ST-segment 
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 Group (a) 4.0 (3.0–5.0) 4.0 (3.0–5.0) 4.0 (3.0–5.0) 0.95
 Group (b) 4.0 (4.0–4.5) NA 4.0 (4.0–4.5) NA
 Group (c) 4.0 (3.5–6.0) 4.0 (3.0–5.0) 5.75 (3.5–9.0) 0.18
2nd control (h)
 Group (a) 16.0 (11.0–
22.0)
13.0 (8.5–16.0) 18.0 (12.0–
26.0)
0.08





 Group (c) 14.0 (10.5–
16.0)
12.0 (7.0–14.0) 16.0 (14.0–
16.0)
0.14
Table 2 Percentage of  cTn result announcement in  time 
of baseline measurement and first and second control
site I centre of maximum care in an urban university setting (University Hospital 
Münster); site II centre of primary care in a rural regional setting (Arnsberg 
Medical Center)
a defined as admission till announcement of baseline results: <60 min (45–
60 min laboratory turn-around time); admission till announcement of results 
of the 1st control: <4 h (control after 3 h + 1 h laboratory turn-around time); 
admission till announcement of results of the 2nd control: <13 h (control after 




Overall (%) Site I (%) Site II (%) p value
Moment of cTn measurement
 Baseline 86.9 94.0 78.9 <0.01*
 1st control 59.4 61.9 57.4 0.93
 2nd control 41.1 52.6 35.1 0.74
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So far, only little has been known about guideline 
adherence in NSTEMI patients within the CPU concept 
[24, 25]. Previous data from the CPU registry on the one 
hand demonstrated that cTn-positive CPU patients were 
faster and more often treated with PCI than cTn-negative 
patients, but on the other hand that there was also a low 
adherence to the standard of care as proposed by the ESC 
guidelines [25]. Rapid rule-out cTn protocols are thought 
to ensure early and facilitated decision-making associ-
ated with more guideline-conforming initiation of CA [3, 
26]. However, as to our knowledge, validation and analy-
sis of the real speed of cTn result announcement within 
the CPU is missing. In our exemplary study, there was 
a significant difference of baseline cTn result announce-
ment in favour of the university institution, which may be 
due to stronger SOPs in that CPU and/or more human 
and technical resources in the corresponding laboratory, 
especially at night or on weekends [27, 28]. Nonetheless, 
times were adequate and mostly below 60  min in both 
sites without a relevant disadvantage of the non-certi-
fied rural regional primary care facility. For the first tro-
ponin control, the guideline-conforming timelines were 
reached less frequently than the baseline measurements 
with a further degradation as far as the second control is 
concerned. Whereas for the first control measurements 
no significant difference was seen for both sites, the 
maximum care university facility provided faster results 
of the second control, pointing towards an assumed 
higher awareness of the benefit of repetitive cTn meas-
urements in site I, again related to a potentially higher 
Table 3 Timing of CA contrasting NSTEMI patients with final diagnosis after the first versus the second cTn control
site I centre of maximum care in an urban university setting (University Hospital Münster); site II centre of primary care in a rural regional setting (Arnsberg Medical 
Center)
subgroups: a–c myocardial infarction without persistent ST-segment elevation (NSTEMI), CA coronary angiography, cTn cardiac troponin
* Statistically significant
Time of CA Overall Site I Site II p value
NSTEMI ensured by the 1st control (h)
 Overall 20.5 h (11.6–45.3 h) 22.0 h (12.3–46.5 h) 20.0 h (10.8–43.5 h) 0.55
 Group (a) 22.0 h (11.0–49.8 h) 23.5 h (12.1–51.1 h) 20.0 h (10.0–40.5 h) 0.35
 Group (b) 15.0 h (7.0–53.8 h) NA 15.0 h (7.0–53.8 h) NA
 Group (c) 21.0 h (13.5–35.0 h) 21.0 h (13.0–30.0 h) 21.3 h (15.0–63.9 h) 0.75
NSTEMI ensured by the 2nd control (h)




 Group (a) 20.0 h (15.5–22.0 h) 10.0 h 21.0 h (18.9–38.5 h)
 Group (b) 22.5 h; 31.0 h NA 22.5 h; 31.0 h
 Group (c) – 27.0 h –
Table 4 Guideline-adherent CA timing within  24  h contrasting NSTEMI patients with  final diagnosis after  the first ver-
sus the second cTn control
site I centre of maximum care in an urban university setting (University Hospital Münster); site II centre of primary care in a rural regional setting (Arnsberg Medical 
Center)
subgroups: a–c myocardial infarction without persistent ST-segment elevation (NSTEMI), CA coronary angiography, cTn cardiac troponin
* Statistically significant
Percentage of CA in time Overall (%) Site I (%) Site II (%) p value
NSTEMI ensured by the 1st control (h)
 Overall 59.1 52.5 64.6 0.76
 Group (a) 57.7 50.0 65.4 0.81
 Group (b) 62.5 NA 62.5 NA
 Group (c) 60.0 57.1 66.7 0.90
NSTEMI ensured by the 2nd control (h)
 Overall 62.5 50.0 66.7 Omitted to due 
remaining small 
sample size
 Group (a) 66.7 50.0 75.0
 Group (b) 50.0 NA 50.0
 Group (c) – – NA
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degree of education of the CPU personal in that maxi-
mum care setting also ensuring certified SOPs [9, 11, 14]. 
In contrast, one still has to reflect that even in that highly 
trained facility timely cTn was available in about two-
thirds (first control) or even worse a half (second control) 
only, allowing for further structural improvement and 
thereby underlining the necessity for such benchmarking 
processes [29].
The continuous development of increasingly sensitive 
cTn tests provides progressively shorter time intervals 
until the diagnosis of an NSTEMI may be confirmed. 
So far, even 2-hour protocols have been introduced 
[30, 31]. Besides this optimism, one should simultane-
ously keep in mind that this development particularly is 
important for those patients with a low to intermediate 
pretest probability without relevant risk markers for an 
early invasive procedure, allowing for early and safe dis-
charge as the gatekeeper for further in-hospital work-up 
[32]. The question remains whether the implementation 
of those rapid protocols also favours a better supply in 
cTn-positive patients with regard to an earlier initiation 
of an invasive regimen [33, 34]. Thus, the timely diagno-
sis and treatment of patients with NSTE-ACS, in contrast 
to patients presenting with STEMI, remains challenging 
[35]. For example, the optimal timing for the invasive pro-
cedure remains uncertain. Recently, some randomized 
trials have investigated the timing of intervention in 
NSTE-ACS patients. Based on these trials, current ESC 
guidelines recommend an immediate invasive strategy 
for hr-NSTE-ACS patients within two hours, an early 
invasive strategy within 24  h for patients with high-risk 
features defined by a GRACE score > 140 and a primary 
high-risk criterion and within 72 h for those at lower risk 
[1]. A more recent trial (LIPSIA-NSTEMI) randomized 
“stable” patients with NSTEMI in an immediate, early 
or selective invasive approach [36]. The authors con-
cluded that in NSTEMI patients an immediate invasive 
approach does not offer an advantage over an early or a 
selective invasive approach with respect to large myocar-
dial infarctions as defined by peak CK-MB levels, which 
is also supported by similar clinical outcomes. According 
to our data, even though there was a significant differ-
ence in the frequency of recommended bypass graft sur-
gery which may be due to the assumption that university 
hospitals provide superior background and frequency in 
performing complex interventions, in general, rates of 
interventions were high, comparable between both sites, 
independent from the accuracy of the rapid rule-out 
protocol and the time of first relevant cTn delta as well 
as comparable to larger recent trials (i.e. ACUITY and 
PLATO) [37–39].
Limitations
The main limitation of this study is the small sample size 
that may bias the results. The inclusion of only two sites 
may not be considered representative for the quality-of-
care evaluation in the entire German CPUs. Second, a 
clinical follow-up for this retrospective analysis was not 
performed, so that the impact of guideline-conforming 
diagnosis and therapy on further cardiovascular events 
remains unsolved for this cohort. Third, the use of differ-
ent cTn assays may have biased the results, especially as 
group (b) was restricted to the high-sensitivity assay of 
site II, only.
Conclusion
After the first years of implementation, our exem-
plary data indicate that German CPUs provide timely 
Table 5 Rates of  intervention including PCI and CABG in NSTEMI patients with final diagnosis after the first versus the 
second cTn control
site I centre of maximum care in an urban university setting (University Hospital Münster); site II centre of primary care in a rural regional setting (Arnsberg Medical 
Center)
subgroups: a–c myocardial infarction without persistent ST-segment elevation (NSTEMI), CA coronary angiography, cTn cardiac troponin
* Statistically significant
Rates of intervention Overall Site I (%) Site II (%) p value
NSTEMI ensured by the 1st control (h)
 Overall 71.6 70.0 72.9 0.82
 PCI 61.4 67.5 56.3 0.73
 CABG 10.2 2.5 16.7 <0.01*
 None 28.4 30.0 27.1 0.82
NSTEMI ensured by the 2nd control (h)




 PCI 75.0 100 66.7
 CABG 16.7 – 16.7
 None 16.7 – 16.7
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identification of cTn-positive patients in a narrow and 
guideline-adherent time frame. Whereas baseline and 
early cTn timing using a rapid rule-out protocol appears 
to be comparable between rural regional primary and 
urban university maximum care facilities, frequency and 
timing of a potential second cTn control is superior in 
the later. Differences in cTn timing did not directly affect 
type and initiation of guideline-conforming CA. How-
ever, its impact on hard end points in terms of cardiovas-
cular events during index stay and follow-up still needs 
to be determined.
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